GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harmony Biosciences Holdings Inc (NAS:HRMY) » Definitions » FCF Margin %

HRMY (Harmony Biosciences Holdings) FCF Margin % : 37.29% (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Harmony Biosciences Holdings FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Harmony Biosciences Holdings's Free Cash Flow for the three months ended in Dec. 2024 was $75.0 Mil. Harmony Biosciences Holdings's Revenue for the three months ended in Dec. 2024 was $201.3 Mil. Therefore, Harmony Biosciences Holdings's FCF Margin % for the quarter that ended in Dec. 2024 was 37.29%.

As of today, Harmony Biosciences Holdings's current FCF Yield % is 11.49%.

The historical rank and industry rank for Harmony Biosciences Holdings's FCF Margin % or its related term are showing as below:

HRMY' s FCF Margin % Range Over the Past 10 Years
Min: -3379.23   Med: 15.01   Max: 37.64
Current: 30.59

During the past 7 years, the highest FCF Margin % of Harmony Biosciences Holdings was 37.64%. The lowest was -3379.23%. And the median was 15.01%.

HRMY's FCF Margin % is ranked better than
94.07% of 1011 companies
in the Biotechnology industry
Industry Median: -137.96 vs HRMY: 30.59

Harmony Biosciences Holdings FCF Margin % Historical Data

The historical data trend for Harmony Biosciences Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harmony Biosciences Holdings FCF Margin % Chart

Harmony Biosciences Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
FCF Margin %
Get a 7-Day Free Trial -3.12 -0.57 32.95 37.64 30.59

Harmony Biosciences Holdings Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.52 20.14 24.29 37.89 37.29

Competitive Comparison of Harmony Biosciences Holdings's FCF Margin %

For the Biotechnology subindustry, Harmony Biosciences Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Harmony Biosciences Holdings's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Harmony Biosciences Holdings's FCF Margin % falls into.


;
;

Harmony Biosciences Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Harmony Biosciences Holdings's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=218.668/714.734
=30.59 %

Harmony Biosciences Holdings's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=75.049/201.267
=37.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harmony Biosciences Holdings FCF Margin % Related Terms

Thank you for viewing the detailed overview of Harmony Biosciences Holdings's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Harmony Biosciences Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harmony Biosciences Holdings Inc (NAS:HRMY) » Definitions » FCF Margin %
Comparable Companies
ARWR KYMR ARQT IRON CGON TVTX AGIO LGND JANX VERA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA, USA, 19462
Website
https://www.harmonybiosciences.com
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Executives
Jeffrey Dierks officer: Chief Commercial Officer 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Sandip Kapadia officer: Chief Financial Officer 450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
Jeffrey M. Dayno officer: Chief Medical Officer 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Marshman Fund Trust Ii 10 percent owner 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Valor Iv Pharma Holdings, Llc 10 percent owner 875 N. MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611
Peter Anastasiou director C/O HARMONY BIOSCIENCES HOLDINGS, INC., 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Andreas Wicki director C/O HBM BIOVENTURES (CAYMAN) LTD., CENTENNIAL TOWERS,STE.305,2454 W.BAY RD., GRAND CAYMAN E9 E9
Jack Nielsen director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Andrew Serafin officer: Chief Business Officer 630 W. GERMANTOWN PIKE, PLYMOUTH MEETING PA 19462
John C Jacobs director, officer: President, CEO 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Linda M Szyper director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050
Eric L Motley director 1516 33RD STREET NW, WASHINGTON DC 20007
R. Mark Graf director C/O DISCOVER FINANCIAL SERVICES, 2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Valor Management L.p. 10 percent owner 875 N. MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611